Curis To Continue Focus On Oncology After Wyeth Ends Hedgehog Venture
This article was originally published in The Pink Sheet Daily
Executive Summary
Cambridge, Mass.-based Curis seeks a new partner to continue small molecule and protein hedgehog agonist development in cardiovascular/nervous system disorders.
You may also be interested in...
Genentech Plans Avastin Glioblastoma sBLA In 2008
Biotech’s Phase III program is focused on line extensions, but earlier-stage pipeline includes multiple NMEs.
Genentech Plans Avastin Glioblastoma sBLA In 2008
Biotech’s Phase III program is focused on line extensions, but earlier-stage pipeline includes multiple NMEs.
Wyeth Ends Bifeprunox For Schizophrenia Development Deal With Solvay
Wyeth decides drug candidate has inadequate commercial value for both companies to share, firm tells "The Pink Sheet" DAILY.